Related Experiment Video

Updated: Jan 2, 2026

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
07:53

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Published on: March 17, 2020

7.6K

Fluvastatin is effective against thymic carcinoma

Keitaro Hayashi1, Yoshimasa Nakazato2, Noriaki Morito1

  • 1Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine, Shimotsuga, Japan.

Life Sciences
|December 2, 2019
PubMed
Abstract

Insights

Fluvastatin effectively suppressed thymic carcinoma cell growth and induced cell death by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR). This study suggests fluvastatin has potential clinical benefits for thymic carcinoma treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Thymic carcinoma is a rare epithelial tumor with no established optimal pharmacotherapies.
  • Investigating novel drug treatments is crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate the effects of fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) inhibitor, on thymic carcinoma.
  • To explore the potential of HMGCR inhibition as a therapeutic strategy for thymic carcinoma.

Main Methods:

  • Thymic carcinoma tissue was surgically excised and HMGCR expression was analyzed using immunohistochemistry.
  • Ty82 human thymic carcinoma cells were treated with varying concentrations of fluvastatin (1-10 μM) to monitor cell growth.

Main Results:

  • HMGCR was found to be expressed on thymic carcinoma cells but not on normal epithelial cells.
  • Fluvastatin treatment suppressed proliferation and induced cell death in Ty82 cells.
  • The antitumor effects were attributed to the blockage of geranylgeranyl-pyrophosphate (GGPP) production, which is essential for cell proliferation.

Conclusions:

  • Fluvastatin demonstrated significant antitumor activity against thymic carcinoma in vitro.
  • These findings suggest that fluvastatin may offer clinical benefits for managing thymic carcinoma.
Keywords:
ERKFluvastatinHMG-CoA reductaseIsoprenylationThymic carcinoma

More Related Videos

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers10:49

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers

Published on: September 26, 2019

5.9K
Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.7K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
416
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
285
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K